title: Equivalence of pulsed-dose-rate to low-dose-rate irradiation in tumor and normal cell lines.
abstract: To determine whether different fractionation schemes could simulate low-dose-rate irradiation, ovarian cells of the carcinoma cell lines A2780s (radiosensitive) and A2780cp (radioresistant) and AG1522 normal human fibroblasts were irradiated in vitro using different fraction sizes and intervals between fractions with an overall average dose rate of 0.53 Gy/h. For the resistant cell line, the three fractionation schemes, 0.53 Gy given every hour, 1.1 Gy every 2 h, and 1.6 Gy every 3 h, were equivalent to low dose rate (0.53 Gy/h). Two larger fraction sizes, 2.1 Gy every 4 h and 3.2 Gy every 6 h, resulted in lower survival than that after low-dose-rate irradiation for the resistant cell line, suggesting incomplete repair of radiation damage due to the larger fraction sizes. The survival for the sensitive cell line was lower at small doses, but then it increased until it was equivalent to that after low-dose-rate irradiation for some fractionation schemes. The sensitive cell line showed equivalence only with the 1.6-Gy fraction every 3 h, although 0.53 Gy every 1 h and 1.1 Gy every 2 h showed equivalence at lower doses. This cell line also showed an adaptive response. The normal cell line showed a sensitization to the pulsed-dose-rate schemes compared to low-dose-rate irradiation. These data indicate that the response to pulsed-dose-rate irradiation is dependent on the cell line and that compared to the response to low-dose-rate irradiation, it shows some equivalence with the resistant carcinoma cell line, an adaptive response with the parental carcinoma cell line, and sensitization with the normal cells. Therefore, further evaluation is required before implementing pulsed-dose-rate irradiation in the clinic.
authors.affiliation: Cancer Research Group, Ottawa Regional Cancer Centre, 501 Smyth Road, Ottawa, Ontario K1H 8L6, Canada.
authors.forename: M
authors.initials: M
authors.lastname: Niedbala
authors.forename: G
authors.initials: G
authors.lastname: Alsbeih
authors.forename: C E
authors.initials: CE
authors.lastname: Ng
authors.forename: G P
authors.initials: GP
authors.lastname: Raaphorst
mesh_terms: D001918:Brachytherapy / Q000379:methods*; D002277:Carcinoma / Q000473:pathology; D002470:Cell Survival / Q000528:radiation effects; D002478:Cells, Cultured / Q000528:radiation effects; D002945:Cisplatin / Q000494:pharmacology; D004249:DNA Damage; D004260:DNA Repair; D019583:Dose Fractionation, Radiation; D004307:Dose-Response Relationship, Radiation; D019008:Drug Resistance, Neoplasm; D005260:Female; D005347:Fibroblasts / Q000528:radiation effects*; D006801:Humans; D008954:Models, Biological; D010051:Ovarian Neoplasms / Q000473:pathology; D011836:Radiation Tolerance; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000528:radiation effects*
chemical_list: D002945:Cisplatin